Services LYNPARZA 50mg
What To Do If You Have Bed.. 27 sleep tips that will make.. LYNPARZA 50mg Vyndaqel 20 mg (tafamidis).. Hydroxyapatite Guaiacol CAS 90-05-1 Orfadin ZYDELIG Tablet Aubagio Tablet KUVAN Tablets Supplier Supplier of Avonex Injection Imbruvica Capsules Exporter Promacta Tablet Supplier Keytruda Injection Supplier Jakafi Exporters Online Oncaspar Supplier Export of Plegridy Injection Opdivo Capsules Online Tecfidera Pill Supplier Tecfidera Medicine Exporters Tracleer Drug Exporters Tysabri Drug Supplier Generic Medicine Exporters Antiviral Medicine Exporter Generic Drug Exporters London Travel Clinic Emergency Response Center,.. Hospital Clinical Services Innovator Samples Supply Medical Supplies Online British Expats WorldWide! The Flying Pharmacy Worldwide Prescriptions Worldwide Pharmaceutical Home.. Medication Verification UK & EU Prescription Service Repeat Prescriptions Unwanted Medicines Emergency Dispensing Pharmaceutical Home Delivery Customer Service Dispensing Services Healthcare Products Online
Derek Clarke is a well-established supplier of LYNPARZA 50mg
Each hard capsule contains 50 mg of olaparib.
For the full list of excipients, see section 6.1.
Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.
Treatment with Lynparza should be initiated and supervised by a physician experienced in the use of anticancer medicinal products.
Patients must have confirmation of a breast cancer susceptibility gene (BRCA) mutation (either germline or tumour) before Lynparza treatment is initiated. BRCA mutation status should be determined by an experienced laboratory using a validated test method (see section 5.1).
There are limited data in patients with somatic BRCA-mutated tumours (see section 5.1).
Genetic counselling for patients with BRCA mutations should be performed according to local regulations
The recommended dose of Lynparza is 400 mg (eight capsules) taken twice daily, equivalent to a total daily dose of 800 mg.
Patients should start treatment with Lynparza no later than 8 weeks after completion of their final dose of the platinum-containing regimen.
It is recommended that treatment be continued until progression of the underlying disease. There are no data on retreatment with Lynparza following subsequent relapse (see section 5.1).
Method of administration
Lynparza is for oral use.
Due to the effect of food on olaparib absorption, patients should take Lynparza at least one hour after food, and refrain from eating preferably for up to 2 hours afterwards
Derek Clarke, with more than 30 years experience as an exporter of both branded and generics medicines, is able to source and supply products, often unavailable through other sources, quickly and efficiently.
For more information on our supplies of Avonex injection please contact us on
e-mail : firstname.lastname@example.org